Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

Patricia Pozo‐Rosich(Vall d'Hebron Institut de Recerca), Eric Pearlman(University of California, San Francisco), Karen Samaan(Eli Lilly (United States)), Todd J. Schwedt(Mayo Clinic in Arizona), Mallikarjuna Rettiganti(Eli Lilly (United States)), Robert A. Nicholson(Eli Lilly (United States))
Advances in Therapy
May 5, 2021
Cited by 12


Related Papers